Glucose-dependent insulinotropic polypeptide (GIP)

GIP is an endogenous incretin hormone released from the gut after nutrient intake. It plays a critical role in glucose metabolism by stimulating insulin secretion in a glucose-dependent manner. While historically studied for its insulinotropic effects, modern research focuses on its systemic roles in adipose tissue, bone remodeling, and the central nervous system, particularly when combined with GLP-1 for metabolic therapies.

GIP is an incretin hormone secreted by the intestine that plays a key role in glucose metabolism and energy homeostasis. While traditionally recognized for its role in stimulating insulin secretion in response to nutrient intake, recent research highlights its involvement in lipid metabolism, bone health, and neurological function. It is currently a focal point of therapeutic development in combination with GLP-1 agonists for treating obesity and metabolic disease.

GIP is a naturally occurring incretin hormone secreted by the intestine after nutrient ingestion. It plays a foundational role in metabolic regulation by stimulating insulin secretion, modulating fat storage, and signaling satiety in the brain. While historically overshadowed by GLP-1, it has recently become a key component in advanced weight loss and diabetes treatments like dual-agonist therapies.

GIP is an incretin hormone naturally secreted by the intestine in response to nutrient intake. It plays a critical role in regulating insulin secretion, fat metabolism, and systemic energy balance. While historically viewed primarily as an insulin-stimulating hormone, recent research—particularly involving dual GIP/GLP-1 receptor co-agonists like tirzepatide—highlights its significant role in weight management and metabolic health.